Moderna (MRNA) Other Non-Current Liabilities (2017 - 2026)

Moderna (MRNA) has reported Other Non-Current Liabilities for 10 consecutive years, with $284.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 2.9% year-over-year to $284.0 million in Q2 2026; TTM through Jun 2026 was $284.0 million, a 2.9% increase from a year earlier, with the FY2025 full-year figure at $285.0 million, up 6.74% from the prior year.
• Other Non-Current Liabilities was $284.0 million for Q2 2026 at Moderna, roughly flat from $283.0 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $285.0 million in Q4 2025 and troughed at $81.0 million in Q3 2022.
• A 5-year average of $218.8 million and a median of $264.0 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities soared 11200.0% in 2022 and advanced 1.81% in 2025, its largest moves.
• Over 5 years, Other Non-Current Liabilities stood at $135.0 million in 2022, then soared by 89.63% to $256.0 million in 2023, then increased by 4.3% to $267.0 million in 2024, then grew by 6.74% to $285.0 million in 2025, then retreated by 0.35% to $284.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $284.0 million (Q2 2026), $283.0 million (Q1 2026), and $285.0 million (Q4 2025), per Business Quant data.